These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34924402)

  • 21. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
    Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calculation of a permitted daily exposure value for the solvent 2-methyltetrahydrofuran.
    Parris P; Duncan JN; Fleetwood A; Beierschmitt WP
    Regul Toxicol Pharmacol; 2017 Jul; 87():54-63. PubMed ID: 28461231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying nonhazardous substances in pharmaceutical manufacturing and setting default health-based exposure limits (HBELs).
    Wiesner L; Araya S; Lovsin Barle E
    J Appl Toxicol; 2022 Sep; 42(9):1443-1457. PubMed ID: 35315528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
    Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.
    Olson MJ; Faria EC; Hayes EP; Jolly RA; Barle EL; Molnar LR; Naumann BD; Pecquet AM; Shipp BK; Sussman RG; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S19-27. PubMed ID: 27233923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Extractable Elements from Elastomers.
    Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
    PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studies.
    Parris P; Martin EA; Stanard B; Glowienke S; Dolan DG; Li K; Binazon O; Giddings A; Whelan G; Masuda-Herrera M; Bercu J; Broschard T; Bruen U; Callis CM; Stults CLM; Erexson GL; Cruz MT; Nagao LM
    Regul Toxicol Pharmacol; 2020 Dec; 118():104802. PubMed ID: 33038429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
    Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
    Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Permitted Daily Exposure Values: Application Considerations in Toxicological Risk Assessments.
    Ball DJ; Beierschmitt WP
    Int J Toxicol; 2020; 39(6):577-585. PubMed ID: 32794434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Risk-Based Approach to Evaluate and Control Elemental Impurities in Therapeutic Proteins.
    Luo Y; Sekhar C; Lee H; Fujimori K; Ronk M; Semin D; Nashed-Samuel Y
    J Pharm Sci; 2020 Nov; 109(11):3378-3385. PubMed ID: 32745562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deriving Compound-Specific Exposure Limits for Chemicals Used in Pharmaceutical Synthesis: Challenges in Expert Decision-Making Exemplified Through a Case Study-Based Workshop.
    Drewe WC; Dobo KL; Sobol Z; Bercu JP; Parris P; Nicolette J
    Int J Toxicol; 2021; 40(3):285-298. PubMed ID: 33525949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cleaning validation of ofloxacin on pharmaceutical manufacturing equipment and validation of desired HPLC method.
    Arayne MS; Sultana N; Sajid SS; Ali SS
    PDA J Pharm Sci Technol; 2008; 62(5):353-61. PubMed ID: 19055231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
    Ellis P; Kenyon M; Dobo K
    Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying and assessing highly hazardous drugs within quality risk management programs.
    Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.